These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36206661)

  • 21. Bioinformatics Analysis Highlight Differentially Expressed CCNB1 and PLK1 Genes as Potential Anti-Breast Cancer Drug Targets and Prognostic Markers.
    Fang L; Liu Q; Cui H; Zheng Y; Wu C
    Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polo-like kinases (Plks) and cancer.
    Takai N; Hamanaka R; Yoshimatsu J; Miyakawa I
    Oncogene; 2005 Jan; 24(2):287-91. PubMed ID: 15640844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.
    Strebhardt K
    Nat Rev Drug Discov; 2010 Aug; 9(8):643-60. PubMed ID: 20671765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom.
    King SI; Purdie CA; Bray SE; Quinlan PR; Jordan LB; Thompson AM; Meek DW
    Breast Cancer Res; 2012 Mar; 14(2):R40. PubMed ID: 22405092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies.
    Syed N; Smith P; Sullivan A; Spender LC; Dyer M; Karran L; O'Nions J; Allday M; Hoffmann I; Crawford D; Griffin B; Farrell PJ; Crook T
    Blood; 2006 Jan; 107(1):250-6. PubMed ID: 16160013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma.
    Weichert W; Denkert C; Schmidt M; Gekeler V; Wolf G; Köbel M; Dietel M; Hauptmann S
    Br J Cancer; 2004 Feb; 90(4):815-21. PubMed ID: 14970859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
    Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
    Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hormonal induction of polo-like kinases (Plks) and impact of Plk2 on cell cycle progression in the rat ovary.
    Li F; Jo M; Curry TE; Liu J
    PLoS One; 2012; 7(8):e41844. PubMed ID: 22870256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Finding Plk3.
    Zimmerman WC; Erikson RL
    Cell Cycle; 2007 Jun; 6(11):1314-8. PubMed ID: 17568195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The lncRNA GATA3-AS1/miR-495-3p/CENPU axis predicts poor prognosis of breast cancer via the PLK1 signaling pathway.
    Lin S; Zhao M; Lv Y; Mao G; Ding S; Peng F
    Aging (Albany NY); 2021 Apr; 13(10):13663-13679. PubMed ID: 33902008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications.
    Weichert W; Kristiansen G; Winzer KJ; Schmidt M; Gekeler V; Noske A; Müller BM; Niesporek S; Dietel M; Denkert C
    Virchows Arch; 2005 Apr; 446(4):442-50. PubMed ID: 15785925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
    Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
    Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [BUB1 gene is highly expressed in gastric cancer:analysis based on Oncomine database and bioinformatics].
    Li X; He J; Yu M; Zhang W; Sun J
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 May; 40(5):683-692. PubMed ID: 32897212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polo-like kinase 3 is associated with improved overall survival in cholangiocarcinoma.
    Juntermanns B; Sydor S; Kaiser GM; Jaradat D; Mertens JC; Sotiropoulos GC; Swoboda S; Neuhaus JP; Meng W; Mathé Z; Baba HA; Canbay A; Paul A; Fingas CD
    Liver Int; 2015 Nov; 35(11):2448-57. PubMed ID: 25818805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The deregulated promoter methylation of the Polo-like kinases as a potential biomarker in hematological malignancies.
    Ward A; Sivakumar G; Kanjeekal S; Hamm C; Labute BC; Shum D; Hudson JW
    Leuk Lymphoma; 2015 Jul; 56(7):2123-33. PubMed ID: 25347426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1.
    Liu J; Lu KH; Liu ZL; Sun M; De W; Wang ZX
    BMC Cancer; 2012 Nov; 12():519. PubMed ID: 23151088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Putative link between Polo-like kinases (PLKs) and Toll-like receptor (TLR) signaling in transformed and primary human immune cells.
    El Maadidi S; Weber ANR; Motshwene P; Schüssler JM; Backes D; Dickhöfer S; Wang H; Liu X; Garcia MD; Taumer C; Soufi B; Wolz OO; Klimosch SN; Franz-Wachtel M; Macek B; Gay NJ
    Sci Rep; 2019 Sep; 9(1):13168. PubMed ID: 31511529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polo-like kinases and the microtubule organization center: targets for cancer therapies.
    Dai W; Cogswell JP
    Prog Cell Cycle Res; 2003; 5():327-34. PubMed ID: 14593727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients.
    Kolosenko I; Goroshchuk O; Vidarsdottir L; Björklund AC; Dowdy SF; Palm-Apergi C
    FASEB J; 2021 May; 35(5):e21476. PubMed ID: 33788972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics.
    Gao Y; Kabotyanski EB; Shepherd JH; Villegas E; Acosta D; Hamor C; Sun T; Montmeyor-Garcia C; He X; Dobrolecki LE; Westbrook TF; Lewis MT; Hilsenbeck SG; Zhang XH; Perou CM; Rosen JM
    Cancer Res Commun; 2021 Dec; 1(3):178-193. PubMed ID: 35156101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.